It depends on the reason and expected benefit. If myelosuppression is holding up RT for cervical cancer patients, then I would not hesitate to give neupogen to avoid or minimize a treatment break. There would be more benefit to neupogen and continuing RT than a downside. Usually, I would try to giv...

This myth that growth factors cannot be safely combined with RT was tested in the 2D era by a protocol done at the JCRT adding etanidazole to chemoradiotherapy for patients with esophageal cancer. We gave patients G-CSF during the weeks they did not receive chemotherapy. This was effective in keepin...

Generally speaking, it is our institutional practice to not hold RT for neupogen/neulasta administration. The only times we would consider is if the patient has a concurrent neutropenic fever.  The history behind holding RT during neupogen administration originated in the era of 3D techniques....

I am still reluctant to add growth factor support during thoracic radiation. Dr. Lilenbaum published in the Journal of Thoracic Oncology in 2010 a phase II trial incorporating colony-stimulating factors to platinum etoposide thoracic radiation with consolidation docetaxel. 26% of patients had grade ...

To revive an old question! Has anyone's practice changed since the publication of the subset analysis evaluating the use of G-CSF in the phase 3 CONVERT trial (Gomes et al., PMID 33545577)? There appeared to be no difference in radiation-related toxicity, mortality, or survival whether or not patien...

I agree that we don't hold RT if the patient has been given Neupogen/Neulasta but I encourage the medical oncologists not to give it for the reasons given by @Elizabeth M. Nichols. When the neutrophil count falls below 500, I will recheck the WBC in 2-3 days and continue radiation as long as the neu...